Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | MAHOGANY: margetuximab and retifanlimab in HER2+, 1L unresectable/metastatic GEA

Daniel V. Catenacci, MD, of the University of Chicago Medical Center, Chicago, IL, updates on Cohort A of the MAHOGANY study (NCT04082364). Patients enrolled in Cohort A were treated with a chemotherapy-free regimen which investigates margetuximab, HER2-targeting monoclonal antibody in combination with retifanlimab in patients with gastroesophageal cancer (GEA). Cohort A was designed in a 1st-line (1L) setting with patients who were double biomarker selected. This was based on the results of a previous study which evaluated margetuximab in combination with pembrolizumab. The primary end-point was response rates in the first 40 patients evaluable in part 1 of Cohort A. The response rate for the first 40 evaluable patients in cohort A was 53%, the median duration of response was 10.3 months and the best disease control rate was 73%. In addition, the median overall survival was not reached and the median progression-free survival was 6.4 months. Overall, these results are very promising as they demonstrate the highest response rates observed with a chemotherapy-free approach in this patient population. Part 2 of the study with cohort A will now proceed, as the response rates met the required benchmark. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.


Dr Catenacci reports disclosures with Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Novartis, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Pierian, Silverback Therapeutics, Servier, Blueprint Medicines, Arcus BiosciencesTempus, Guardant Health, Archer & Natera.